Pancreatic Cancer Treatment Market Analysis By Affected Region (Exocrine, Endocrine), By Type (Chemotherapy, Targeted Therapy, Others), By Region (North America, Europe, Asia Pacific, Latin America And MEA), And Segment Forecasts, 2018 - 2025

Industry Insights

The global pancreatic cancer treatment market size was valued at USD 1.7 billion in 2015. The rising prevalence of obesity, alcohol consumption, and smoking is expected to propel the market growth. In addition, growing geriatric population is expected drive the growth of the pancreatic cancer treatment industry during the forecast period. Apart from lifestyle-dependent factors, a personal or family history of pancreatitis and BRCA2 mutation predisposes a person to pancreatic cancer.

A number of imaging techniques such as CT scan, MRI, and ultrasound are used for diagnosis of the disease. Chemotherapy is the most common form of treatment provided by medical practitioners and oncologists. Currently, there are only four drugs approved by the U.S. FDA for the treatment of pancreatic cancer: ABRAXANE, (albumin-bound paclitaxel); Gemzar (gemcitabine); 5-FU (fluorouracil); and ONIVYDE (irinotecan liposome injection). Apart from these four drugs, FOLFIRINOX, a combination of three chemotherapy drugs (5-FU/leucovorin, irinotecan, and oxaliplatin) is commonly used in the treatment of metastatic pancreatic adenocarcinoma. Other emerging chemotherapies for advanced pancreatic cancer combined with agents already approved for use are being investigated in clinical trials.

U.S. pancreatic cancer treatment market, by affected region, 2014-2025 (USD Million)

In developing countries, governments are continuously investing huge amount of funds to improve patient-centered care. Increasing geriatric population base, rising prevalence of pancreatic cancer cases, and rapid growth in foreign investments are expected to be witnessed over the forecast period in the developing nations of Asia Pacific and Middle East region.

Affected Region Insights

The global pancreatic cancer treatment industry has been segmented into type of affected region and application. The affected region segment is categorized into exocrine and endocrine. Most of the pancreatic cancers diagnosed in the world belong to exocrine category, thus the segment currently dominates the market. The endocrine type of cancers, although less prevalent, are still awaiting effective treatment modalities.

The investment on R&D is significant in both types of cancers. However, the increasing prevalence and growing reach of novel techniques in the developing regions are the factors expected to drive the growth of the exocrine segment throughout the forecast period.

Type Insights

Based on type, the pancreatic cancer market is segmented into chemotherapy, targeted therapy, and others that mainly include surgery, radiation techniques, and other therapies. Targeted therapy dominated the market in 2015 and is expected to dominate throughout the forecast period.

The factors driving growth include introduction of the novel biologic therapies and targeted drugs in order to minimize the adverse effects of the existing therapies, including chemotherapy. Demand for targeted drugs is expected to rise significantly during the forecast period.

Global pancreatic cancer treatment market, by type, 2015

Regional Insights

North America dominated the pancreatic cancer treatment industry with largest revenue share in 2015. The dominance of this region is mainly attributed to the improved healthcare infrastructure, high adoption of pancreatic treatment procedures, and the presence of large target population. In addition, increasing incidence of pancreatic cancer is aggressively propelling the demand for treatment options.

On the other hand, Asia Pacific is expected to witness the fastest growth during the forecast period. Presence of well-established hospitals and critical care centers as well as large population suffering from pancreatic cancer would boost the growth of the market in Asia Pacific region. Furthermore, with growing number of pancreatic cancer cases in the Asia Pacific region, the diagnosis and treatment of pancreatic cancer in the region must adhere to the same regimen as followed in the western countries.

Competitive Insights

Currently, the global pancreatic cancer treatment industry is consolidated in nature with only a few top companies capturing the major share of the market. Some of the top companies operating in this market are Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.

Numerous companies are focusing on the introduction of technologically advanced products in order to gain a foothold in the fast-developing medical devices sector. In addition, partnerships, collaborations, and mergers with well-established players are the major strategies deployed by top players to increase the market share during the forecast period.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels as well as provides an analysis on the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the Pancreatic Cancer Treatment Market on the basis of affected region, type, and region:

• Affected region Outlook (Revenue, USD Million, 2014 - 2025)

  • Exocrine

  • Endocrine

• Type Outlook (Revenue, USD Million, 2014 - 2025)

  • Chemotherapy

  • Targeted Therapy

  • Others

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa